Novavax Inc (NVAX)
Healthcare
Biotechnology
7.40 $
+1.2%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns Novavax Inc (NVAX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.0% of the shares are freely tradable; institutional investors hold 69.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
69.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
5.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
86.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
26.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
164Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Shah Capital Management | 9.03 | 14,845,097 | +2.0 | 03/31/2026 |
| BlackRock Inc | 7.81 | 12,844,319 | -0.4 | 03/31/2026 |
| State Street Corp | 5.46 | 8,970,518 | -5.8 | 03/31/2026 |
| D. E. Shaw & Co LP | 4.69 | 7,709,858 | +28.7 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.35 | 7,151,625 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.34 | 7,130,147 | +0.0 | 03/31/2026 |
| Sanofi | 4.18 | 6,880,481 | +0.0 | 06/30/2026 |
| Bank of America Corp | 4.04 | 6,637,213 | -19.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 4.53 | 7,448,165 | +0.6 | 07/29/2026 |
| Vanguard Morn Total Stk Mkt Idx Investor | 3.16 | 5,197,170 | +1.2 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.